Discover the Power of a Revolution in Heart Failure

Heart Failure is considered a global pandemic. A recent study confirms that Heart failure affects over 26 million people worldwide and the prevalence will increase with the ageing population. Despite the substantial advancements in therapies morbidity and mortality are still high and quality of life continues to be poor for these Heart failure patients.1

Adherence to medication and optimization of standard care is a continued need in managing Heart Failure patients to reduce symptoms, hospitalization and death.2 The Servier Heart Failure Franchise provides a solution in the management of all Heart failure patients. ESC 2021 guidelines outlines the needs to uptitrate to higher dose Bblocker, ACEI and control Heart Rate below 70bpm in order to reduce symptoms, hospitalization and death. Servier provides the trilogy of life in managing newly diagnosed Heart failure patients or Heart Failure patients already treated with a bblocker.3

Heart Failure is associated with a poor prognosis; approximately 50% of patients will die within 5 years after diagnoses. Lack of treatment optimization and/or non-adherence to treatment guidelines results in higher risk of cardiovascular events and unnecessary costs from a high risk of rehospitalization and death